For informational purposes only — not investment advice

← Back to signals

MDLN

LONGINSIDER SELL

MEDLINE INC

Research: Finviz ↗·Perplexity ↗

Funds
3
Score
4.71
vs SPY
+15.2%
Stock return (since Q-end)
+9.1%
SPY return (since Q-end)
-6.1%
Current price
$37.84
Days to cover (short int.)
3.8d↓-28.2%
as of 2026-10-30 · shares short vs 2026-09-30

News Summary

Negative

Medline delivered strong Q3 2026 revenue growth of 10.4% ($7.9B), but this has been severely overshadowed by an FDA warning letter on manufacturing quality violations, remediation costs that impacted Q2 earnings, and multiple sharp stock declines (down to 52-week low of $31.37). Ongoing securities fraud investigations by multiple law firms and significant analyst downgrades reflect loss of investor confidence despite solid topline performance.

Red flags

  • •FDA warning letter (June 2, 2026) detailing significant violations of Current Good Manufacturing Practice regulations
  • •Acknowledged remediation efforts resulted in material earnings loss in Q2 2026
  • •Stock declined 7% on June 2, 13% on August 5, and 12.8% in early October; now at 52-week low of $31.37
  • •Multiple securities fraud investigations by BFA Law, Kirby McInerney, Kaplan Fox, and Pomerantz ongoing as of October 2026
  • •Analyst downgrades including Zacks 'strong sell' and price target cuts from Barclays ($45→$43) and BofA ($53→$46)
  • •Potential litigation exposure and reputational damage to major healthcare supplier

Funds Buying (3)

FundManagerShares Held∆ SharesPosition Value% of FundQoQStatus
Maverick CapitalLee Ainslie7.0M+7.0M$244M2.0%—NEW
Durable Capital PartnersHenry Ellenbogen4.7M+2.1M$164M1.7%+80%Existing
ValueAct HoldingsMason Morfit4.2M+4.2M$144M2.3%—NEW

Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.

Portfolio Context

Where MDLN ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.

ValueAct Holdings

position #12 of this fund's book

  1. 9TOAST INC$237M
  2. 10LIBERTY LIVE HOLDINGS INC$200M
  3. 11AGILENT TECHNOLOGIES INC$182M
  4. 12MEDLINE INC$144M
  5. 13GALLAGHER ARTHUR J & CO$137M
  6. 14RYAN SPECIALTY HOLDINGS INC$136M
  7. 15SIMPSON MFG INC$134M
Maverick Capital

position #19 of this fund's book

  1. 16REPLIGEN CORP$272M
  2. 17MONSTER BEVERAGE CORP NEW$269M
  3. 18SNOWFLAKE INC$259M
  4. 19MEDLINE INC$244M
  5. 20SHERWIN WILLIAMS CO$241M
  6. 21EQUITY LIFESTYLE PROPERTIES$236M
  7. 22CAMDEN PPTY TR$230M
Durable Capital Partners

position #20 of this fund's book

  1. 17REVVITY INC$202M
  2. 18UL SOLUTIONS INC$190M
  3. 19FLOWSERVE CORP$189M
  4. 20MEDLINE INC$164M
  5. 21VSE CORP$142M
  6. 22WARBY PARKER INC$139M
  7. 23TTM TECHNOLOGIES INC$133M

Values are quarter-end position sizes. Shown only for funds where MDLN ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.

Signal History

QuarterDirectionFundsScorevs SPY
Q3 2026LONG34.71+15.2%
Q2 2026SHORT43.70-0.0%
Q1 2026LONG44.85-39.4%

Same issuer appearing in consecutive quarters — persistent institutional conviction. Returns are frozen at each archived quarter's last refresh.

Insider Activity

NameTitleTypeSharesPriceValueFiledSrc
GIC Private Ltd—SELL7.8M$35.15$274.77M2026-10-08↗
GIC Private Ltd—SELL2.1M$35.05$73.22M2026-10-06↗
GIC Private Ltd—SELL7.2M$35.05$251.76M2026-10-06↗
GIC Private Ltd—SELL1.7M$35.78$60.42M2026-10-05↗
GIC Private Ltd—SELL2.6M$35.35$90.88M2026-10-02↗
GIC Private Ltd—SELL7.1M$34.33$245.35M2026-10-02↗

Beneficial Ownership (13D/13G)

FilerFormShares% of ClassFiledSrc
Capital Research Global InvestorsSC 13G47.8M5.4%2026-11-13↗
GIC Private LimitedSC 13G/A74.6M8.5%2026-11-06↗
GIC Private LimitedSC 13G/A114.4M13.0%2026-10-30↗
Hellman & Friedman Capital Partners X (Parallel), L.P.SC 13G/A61.1M6.4%2026-08-11↗
BX Mozart ML-2 Holdco L.P.SC 13G/A89.5M10.2%2026-08-07↗
FMR LLCSC 13G46.9M5.5%2026-08-06↗

SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.